Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer
Purpose: Preclinical findings suggest that adding targeted therapies to combination radiation-chemotherapy can enhance treatment efficacy; however, this approach may enhance normal tissue toxicity. We investigated the maximum tolerated dose, dose-limiting toxicities, and response rate when the selec...
Main Authors: | Ritsuko eKomaki, Xiong eWei, Pamela K Allen, Zhongxing eLiao, Luka eMilas, James D Cox, Michael S O'Reilly, Joe eChang, Mary Frances McAleer, Melenda eJeter, George R Blumenschein, Merrill S Kies |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00052/full |
Similar Items
-
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
by: Johnson C, et al.
Published: (2020-01-01) -
Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment
by: N. V. Chichasova, et al.
Published: (2004-02-01) -
The role of celecoxib in glioblastoma treatment: a review of literature
by: F. Tavakolian, et al.
Published: (2020-07-01) -
CELEBREX IN TREATMENT OF VERTEBRAL PAIN SYNDROME IN SYSTEMICV LUPUS ERYTHEMATOSUS
by: N. P. Shilkina, et al.
Published: (2002-06-01) -
Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study
by: Wenxin Hong, et al.
Published: (2020-11-01)